Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 25 - Molecular imaging of Alzheimer's disease

  • from Section IV - Cognitive Disorders
    • By Norbert Schuff, Center for Imaging of Neurodegenerative Diseases at the Veterans Affairs Medical Center and Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco, CA, USA
  • Edited by Martha E. Shenton, Bruce I. Turetsky, University of Pennsylvania
  • Book:
    Understanding Neuropsychiatric Disorders
    Published online:
    10 January 2011
    Print publication:
    09 December 2010, pp 351-360

  • Summary

    Neurochemical imaging offers an opportunity to study at a molecular level in-vivo the neuronal substrates that underpin Alzheimer's disease (AD) and related disorders, such as mild cognitive impairment (MCI). Proton magnetic resonance spectroscopic imaging (1H MRSI) measures have the potential of offering a relatively direct window into neurochemical alterations in the brain. This chapter reviews key findings of 1H MRSI in AD, MCI and aging, and discusses the potential value of this technology for diagnosis and prognosis of AD as well as for the assessment of therapeutic intervention. Other promising neurochemical imaging modalities that directly probe neurotransmitter systems using radioactive positron emission tomography (PET) tracers and amyloid PET imaging are also discussed. Overall, MRS is a promising investigational technique in dementia and related cognitive disorders to provide unique measures of multivariate spectroscopic profiles of the brain.